Gate Bioscience is a preclinical biotechnology company creating a new class of medicines called Molecular Gates. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin: inside the cell. The company's mission is to eliminate diseases for patients by targeting disease-causing proteins through a completely new therapeutic mechanism.

Gate Bioscience is a preclinical biotechnology company creating a new class of medicines called Molecular Gates. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin: inside the cell. 

Humans produce over 4,000 distinct extracellular proteins, more than 1,000 of which can drive disease when they act improperly, misfold, or are made at the wrong time, in the wrong place, or at incorrect levels. By eliminating these disease-causing proteins, we aim to eliminate diseases for patients.

Molecular Gates act by a completely new therapeutic mechanism. All extracellular proteins pass through single channel in the cell as they are secreted into the body. Molecular Gates bind to this channel, setting up a “gate” that recognizes and blocks a specific, disease-causing protein from exiting. With nowhere to go, the harmful protein is degraded by the cell instead of being secreted.

Our mission to create Molecular Gate medicines is backed by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. Learn more at www.gatebio.com.

Gate Bioscience

As 2023 draws to a close, we're reflecting on the last 365 days of Gate Bioscience. We're proud of everything our exceptional team has accomplished, and we're profoundly grateful for everyone who's been a part of our journey so far. 

Thank you to all our employees, partners, collaborators, advisors, and investors who have contributed to Gate's momentum this year—and may your 2024 be full of exciting science, discoveries, and growth!

Tune into the Bio Eats World podcast to hear our CEO and cofounder Jordi Mata-Fink talk with Vineeta Agarwala, MD PhD and Ben Portney from a16z Bio + Health about Gate Bioscience and building a novel scientific platform. 

They get geeky about:

 🔬 Extracellular proteins and how they cause diseases
 💊 Why small molecules rock (or, as Vineeta calls them, "the OGs of our therapeutic arsenal")
 🤝 Bringing together the right team
 🚀 The power of a platform in drug discovery
 🍗 Gate's "barbecue of discovery"

Take a listen for all this and more wherever you get your favorite podcasts!

Looking for a podcast for your commute to or from work? 

Tune into Labiotech.eu's latest episode of Beyond Biotech to hear our CEO and Co-Founder, Jordi Mata-Fink, talk with Host Jim Cornall about Gate's science, the promise of Molecule Gate medicines for diseases driven by extracellular proteins, and our vision for this new class of medicines.

🔉 Listen: https://apple.co/3sSdO7f 🔉
🔬 Read more: https://bit.ly/3N3rCmp 🔬

Curious about Gate and our science? Lei Lei Wu has the details in Endpoints News today. 

Check out her article to hear more about the secretory translocon and the powerful potential of Molecular Gate medicines from our Co-Founder and CEO Jordi Mata-Fink and our BOD members and investors Vineeta Agarwala, MD PhD (a16z Bio + Health) and Clare Ozawa (Versant Ventures).

💊 🗞 Click to read more! 💊 🗞

Today’s a big day for Gate Bioscience—we’ve emerged from stealth, unveiling our science, Molecular Gate medicines, our platform, and $60M in funding from Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV (Google Ventures). Come take a look at our press release to learn more about our science, leadership team, and our vision for Molecular Gate medicines. 

https://lnkd.in/efRmE_zJ

COM:GATEBIO

Gate Bioscience

Analysis Not Available